CXCL5 expression is associated with active signals of macrophages in the microenvironment of papillary thyroid carcinoma

  • 0Department of Pathology, University Medical Center, Ho Chi Minh City 70000, Viet Nam.

|

|

Summary

This summary is machine-generated.

High C-X-C motif chemokine ligand 5 (CXCL5) expression indicates advanced papillary thyroid carcinoma (PTC) and poor prognosis. CXCL5 may be a therapeutic target for advanced PTC, impacting tumor immunology and microenvironment.

Area Of Science

  • Oncology
  • Immunology
  • Molecular Biology

Background

  • C-X-C motif chemokine ligand 5 (CXCL5) is a granulocyte-attracting chemokine implicated in papillary thyroid carcinoma (PTC) progression.
  • The in vivo effects of CXCL5 on PTC tumor cells and their microenvironment remain largely unelucidated.

Purpose Of The Study

  • To investigate the biological effects of CXCL5 on PTC tumor cells.
  • To analyze the impact of CXCL5 on the tumor microenvironment.
  • To determine the association of CXCL5 with clinical progression in PTC.

Main Methods

  • Utilized The Human Cancer Genome Atlas (TCGA) - thyroid carcinoma (THCA) dataset comprising 500 PTC patients.
  • Performed differential gene expression analysis (DEA) and pathway analysis on CXCL5 expression.
  • Correlated CXCL5 expression with immune profiles, microenvironment components, and clinical outcomes.

Main Results

  • CXCL5 expression was significantly associated with specific genes (PBPP, SLC11A1, MRC1) and immune profiles.
  • Higher CXCL5 expression correlated with increased activity in RAS-RAF, NF-kB, PRC2, IL2, IL5, and Wnt pathways.
  • CXCL5 strongly correlated with macrophage activity and served as an indicator for advanced tumor stage, nodal metastasis, and poorer prognosis in PTC.

Conclusions

  • CXCL5 is a significant biomarker for PTC, closely linked to tumor immunology and microenvironment.
  • Elevated CXCL5 expression signifies more advanced disease and worse prognosis in PTC patients.
  • Targeting CXCL5 presents a potential therapeutic strategy for advanced PTC.